2Seventy Bio Inc Total Assets
2Seventy Bio Inc total assets. Based on the latest financial reports, 2Seventy Bio Inc (TSVT) holds total assets worth $480.00 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 2Seventy Bio Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of 2Seventy Bio Inc (2019–2024)
Total assets of 2Seventy Bio Inc from 2019 to 2024. This chart illustrates how 2Seventy Bio Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for 2Seventy Bio Inc for real-time trading data and today's change.
2Seventy Bio Inc - Asset Composition Analysis
2Seventy Bio Inc Total Assets Breakdown (December 2024)
2Seventy Bio Inc total assets breakdown as of December 2024. 2Seventy Bio Inc's total assets of $480.00 Million consist of 39.1% current assets and 61.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.9% |
| Accounts Receivable | $7.78 Million | 1.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.88 Million | 1.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 2Seventy Bio Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 2Seventy Bio Inc's current assets represent 39.1% of total assets in 2024, an increase from 6.6% in 2019.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2024, up from -42.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
2Seventy Bio Inc Competitors by Total Assets
Key competitors of 2Seventy Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
2Seventy Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.80 | 3.52 | 0.18 |
| Quick Ratio | 4.80 | 3.72 | 0.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $157.19 Million | $152.44 Million | $-85.16 Million |
2Seventy Bio Inc - Advanced Valuation Insights
This section examines the relationship between 2Seventy Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | -15.2% |
| Total Assets | $479.51 Million |
| Market Capitalization | $266.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values 2Seventy Bio Inc's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 2Seventy Bio Inc's assets decreased by 15.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 2Seventy Bio Inc (2019–2024)
The table below shows the annual total assets of 2Seventy Bio Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $479.51 Million | -15.19% |
| 2023-12-31 | $565.43 Million | -13.89% |
| 2022-12-31 | $656.66 Million | -13.56% |
| 2021-12-31 | $759.67 Million | +143.00% |
| 2020-12-31 | $312.62 Million | -0.74% |
| 2019-12-31 | $314.95 Million | -- |
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more